Related Experiment Video
Updated: Mar 3, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Reappraisal of TDP-43 pathology in FTLD-U subtypes
Ian R Mackenzie1, Manuela Neumann2
1Department of Pathology, Vancouver General Hospital, University of British Columbia, 855 West 12th Avenue, Vancouver, BC, V5Z 1M9, Canada. ian.mackenzie@vch.ca.
Abstract:
Frontotemporal lobar degeneration with tau-negative, ubiquitin-immunoreactive (-ir) pathology (FTLD-U) is subclassified based on the type and cortical laminar distribution of neuronal inclusions. Following the discovery of the transactive response DNA-binding protein Mr 43 kD (TDP-43) as the ubiquitinated protein in most FTLD-U, the same pathological criteria have been used to classify FTLD cases based on TDP-43-ir changes. However, the fact that immunohistochemistry (IHC) for ubiquitin and TDP-43 each recognizes slightly different pathological changes in these cases means that the original FTLD-U subtype criteria may not be directly applicable for use with TDP-43 IHC. We formally re-evaluated the TDP-43-ir pathological features that characterize the different FTLD-U subtypes to see if the current classification could be refined. In our series of 78 cases, 81% were classified as one of the common FTLD-U subtypes (29% A, 35% B, 17% C). With TDP-43 IHC, each subtype demonstrated consistent intra-group pathological features and clear inter-group differences. The TDP-43-ir changes that characterized type A and C cases were similar to those seen with ubiquitin IHC; specifically, compact neuronal cytoplasmic inclusions (NCI), short thick dystrophic neurites (DN), and lentiform neuronal intranuclear inclusions concentrated in cortical layer II in type A cases, and a predominance of long thick DN in type C. However, type B cases showed significant differences with TDP-43 compared with ubiquitin IHC; with many diffuse granular NCI and wispy thread and dots-like profiles in all cortical layers. The remaining 15 cases (12 with C9orf72 mutations) showed changes that were consistent with combined type A and type B pathology. These findings suggest that the pathological criteria for subtyping FTLD cases based on TDP-43 IHC might benefit from some refinement that recognizes differences in the morphologies of NCI and neurites. Furthermore, there is a significant subset of cases (most with the C9orf72 mutation) with the pathological features of multiple FTLD-TDP subtypes for which appropriate classification is difficult.
Insights
This study refines classification of frontotemporal lobar degeneration with TDP-43 pathology. Findings suggest current criteria need adjustment for accurate subtyping of FTLD-TDP cases.
Area of Science:
- Neuropathology
- Neurodegenerative Diseases
- Molecular Biology
Background:
- Frontotemporal lobar degeneration with tau-negative, ubiquitin-immunoreactive pathology (FTLD-U) is subclassified by neuronal inclusion type and distribution.
- Transactive response DNA-binding protein 43 kDa (TDP-43) is the primary ubiquitinated protein in most FTLD-U cases.
- Current FTLD-U classification criteria, based on ubiquitin immunohistochemistry (IHC), may not perfectly translate to TDP-43 IHC due to subtle differences in detected pathological changes.
Purpose of the Study:
- To formally re-evaluate TDP-43-immunoreactive pathological features in FTLD-U subtypes.
- To refine the existing classification system for FTLD based on TDP-43 immunohistochemistry.
- To assess the applicability of current FTLD-U subtype criteria using TDP-43 IHC.
Main Methods:
- Retrospective analysis of 78 cases with frontotemporal lobar degeneration.
- Immunohistochemistry (IHC) for ubiquitin and TDP-43 was performed.
- Systematic evaluation of neuronal inclusions (neuronal cytoplasmic inclusions - NCI, dystrophic neurites - DN) and their distribution.
Main Results:
- 81% of cases were classified into common FTLD-U subtypes (A, B, C) using TDP-43 IHC.
- TDP-43 IHC revealed consistent intra-group features and clear inter-group differences for subtypes A and C, largely mirroring ubiquitin IHC findings.
- Type B cases showed distinct TDP-43 IHC profiles with diffuse granular NCI and thread-like profiles, differing significantly from ubiquitin IHC. Fifteen cases, including 12 with C9orf72 mutations, exhibited features of multiple FTLD-TDP subtypes.
Conclusions:
- Pathological criteria for subtyping FTLD-TDP may require refinement to account for variations in NCI and neurite morphology observed with TDP-43 IHC.
- A significant subset of cases, particularly those with C9orf72 mutations, present with mixed FTLD-TDP pathological features, complicating classification.
- Further research is needed to optimize diagnostic criteria for complex FTLD-TDP cases.
More Related Videos
06:58Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles
Published on: October 18, 2024
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015